FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 346:1682-1683 May 30, 2002 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Jonas, M. M. PubMed Citation

Chronic hepatitis B remains a major public health problem, affecting more than 350 million people worldwide. Cirrhosis, liver failure, or hepatocellular carcinoma will develop in approximately 15 to 40 percent of infected patients.

The worldwide prevalence of carriage of hepatitis B virus (HBV) ranges from 0.1 to 20 percent. The wide range is largely related to differences in age at the time of infection — a factor that is inversely related to the risk of chronic infection. Perinatal infection is the predominant mode of transmission in high-prevalence areas, and horizontal transmission during early childhood is the most common form in . . . [Full Text of this Article]

This article has been cited by other articles:

• Jost, S., Turelli, P., Mangeat, B., Protzer, U., Trono, D. (2007). Induction of Antiviral Cytidine Deaminases Does Not Explain the Inhibition of Hepatitis B Virus Replication by Interferons. J. Virol. 81: 10588-10596 [Abstract] [Full Text]  
• Davaalkham, D., Ojima, T., Wiersma, S., Lkhagvasuren, T., Nymadawa, P., Uehara, R., Watanabe, M., Oki, I., Nakamura, Y. (2007). Administration of hepatitis B vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide survey. J. Epidemiol. Community Health 61: 578-584 [Abstract] [Full Text]  
• Medicherla, S., Protter, A. A., Ma, J. Y., Mangadu, R., Almirez, R., Koppelman, B., Kerr, I., Navas, T. A., Movius, F., Reddy, M., Liu, Y.-W., Luedtke, G., Perumattam, J., Mavunkel, B., Dugar, S., Schreiner, G. F. (2006). Preventive and Therapeutic Potential of p38{alpha}-Selective Mitogen-Activated Protein Kinase Inhibitor in Nonobese Diabetic Mice with Type 1 Diabetes. J. Pharmacol. Exp. Ther. 318: 99-107 [Abstract] [Full Text]  
• Peng, J., Zhao, Y., Mai, J., Pang, W. K., Wei, X., Zhang, P., Xu, Y. (2005). Inhibition of hepatitis B virus replication by various RNAi constructs and their pharmacodynamic properties. J. Gen. Virol. 86: 3227-3234 [Abstract] [Full Text]  
• Chang, J. J., Wightman, F., Bartholomeusz, A., Ayres, A., Kent, S. J., Sasadeusz, J., Lewin, S. R. (2005). Reduced Hepatitis B Virus (HBV)-Specific CD4+ T-Cell Responses in Human Immunodeficiency Virus Type 1-HBV-Coinfected Individuals Receiving HBV-Active Antiretroviral Therapy. J. Virol. 79: 3038-3051 [Abstract] [Full Text]  
• Rivkin, A. M (2004). Adefovir Dipivoxil in the Treatment of Chronic Hepatitis B. The Annals of Pharmacotherapy 38: 625-633 [Abstract] [Full Text]  
• Mailliard, M. E., Gollan, J. L. (2003). Suppressing Hepatitis B without Resistance -- So Far, So Good. NEJM 348: 848-850 [Full Text]